ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 180 filers reported holding ASCENDIS PHARMA A/S in Q1 2021. The put-call ratio across all filers is 1.02 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $11,611 | -21.2% | 124 | -24.8% | 0.00% | – |
| Q2 2023 | $14,726 | -33.0% | 165 | -19.5% | 0.00% | – |
| Q1 2023 | $21,980 | -94.2% | 205 | -95.0% | 0.00% | -100.0% |
| Q2 2022 | $380,000 | -20.8% | 4,093 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $480,000 | -12.9% | 4,093 | 0.0% | 0.00% | -33.3% |
| Q4 2021 | $551,000 | -15.5% | 4,093 | 0.0% | 0.00% | -25.0% |
| Q3 2021 | $652,000 | +21.2% | 4,093 | 0.0% | 0.00% | +33.3% |
| Q2 2021 | $538,000 | -13.6% | 4,093 | -15.4% | 0.00% | -25.0% |
| Q1 2021 | $623,000 | -22.8% | 4,837 | 0.0% | 0.00% | -20.0% |
| Q4 2020 | $807,000 | +29.1% | 4,837 | +19.4% | 0.01% | +25.0% |
| Q3 2020 | $625,000 | +4.3% | 4,052 | 0.0% | 0.00% | -20.0% |
| Q2 2020 | $599,000 | +90.8% | 4,052 | +45.5% | 0.01% | +66.7% |
| Q1 2020 | $314,000 | -18.9% | 2,785 | 0.0% | 0.00% | 0.0% |
| Q4 2019 | $387,000 | – | 2,785 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 7,387,900 | $1,177,557,000 | 16.32% |
| Q Global Advisors, LLC | 66,714 | $10,634,000 | 8.85% |
| Ghost Tree Capital, LLC | 120,000 | $19,127,000 | 5.59% |
| Vivo Capital, LLC | 760,606 | $121,233,000 | 5.44% |
| Spyglass Capital Management LLC | 1,378,887 | $219,781,000 | 5.04% |
| Avoro Capital Advisors LLC | 1,980,000 | $315,592,000 | 4.96% |
| Eversept Partners, LP | 445,203 | $70,960,906 | 4.93% |
| Sofinnova Investments, Inc. | 499,824 | $79,667,000 | 4.72% |
| Eventide Asset Management | 1,748,648 | $278,717,000 | 3.68% |
| Baker Brothers Advisors | 4,541,604 | $723,886,000 | 3.18% |